Company Overview of Kadmon Holdings, LLC
Kadmon Holdings, LLC, a biopharmaceutical company, discovers, develops, and commercializes small molecules and biologics to address unmet medical needs. The company markets and distributes a portfolio of branded generic ribavirin products for chronic hepatitis C virus infection; co-promotes a product for chronic weight management; distributes products for chorea, cytomegalovirus retinitis, and for the prevention of CMV disease. It is also developing product candidates in autoimmune and fibrotic diseases, oncology, and genetic diseases. The company is headquartered in New York, New York.
450 East 29th Street
New York, NY 10016
Key Executives for Kadmon Holdings, LLC
Chief Executive Officer, President and Director
Total Annual Compensation: $1.0M
Chief Financial Officer and Executive Vice President
Total Annual Compensation: $515.4K
Chief Administrative, Compliance & Legal Officer, Executive Vice President and General Counsel
Total Annual Compensation: $500.0K
Compensation as of Fiscal Year 2015.
Kadmon Holdings, LLC Key Developments
Kadmon Initiates Phase 2 Clinical Trial Evaluating KD025 in Chronic Graft-Versus Host Disease
Sep 21 16
Kadmon Holdings Inc. announced that the first patient has been dosed in a Phase 2 clinical trial of KD025, the Company’s rho-associated coiled-coil kinase 2 (ROCK2) inhibitor, for the treatment of chronic graft-versus-host disease (cGVHD). The randomized, open-label, 24-week study examines the safety, tolerability and activity of KD025 dosed at 200 mg once daily (QD), 200 mg twice daily (BID) or 400 mg QD in 48 cGVHD patients in the United States. cGVHD is a common and often fatal complication following allogeneic stem cell transplantation in which donor immune cells attack the recipient’s body, leading to fibrosis in multiple organs. Preclinical research conducted by Kadmon in collaboration with Bruce Blazar, MD, of the University of Minnesota and recently published in the journal Blood demonstrated that ROCK2 inhibition with KD025 down-regulated clinical symptoms in multiple murine models of cGVHD. KD025 treatment also down-regulated the pro-inflammatory signaling pathways involved in cGVHD pathogenesis and simultaneously up-regulated regulatory cell function in these murine models, reducing overall cGVHD progression while preserving normal immune function. In addition to cGVHD, Kadmon is investigating the potential of KD025 to treat other autoimmune and fibrotic diseases. The company is conducting an ongoing Phase 2 clinical study of KD025 for the treatment of idiopathic pulmonary fibrosis, with a planned Phase 2 study in moderate to severe psoriasis.
Kadmon Holdings, LLC Presents at 2016 BIO Investor Forum, Oct-18-2016 10:00 AM
Sep 15 16
Kadmon Holdings, LLC Presents at 2016 BIO Investor Forum, Oct-18-2016 10:00 AM. Venue: Westin St. Francis Hotel, 335 Powell Street, San Francisco, CA 94102, United States. Speakers: Harlan W. Waksal, Chief Executive Officer, President and Director.
Eva Heyman to Resign from Kadmon Holdings, Inc. as Executive Vice President, Chief Commercial Officer, Effective September 30, 2016
Sep 13 16
On September 7, 2016, Eva Heyman informed Kadmon Holdings Inc. that she will resign from the Company as Executive Vice President, Chief Commercial Officer, to pursue other opportunities. Ms. Heymans resignation is effective on September 30, 2016.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|